Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01935128 · ClinicalTrials.gov registry record · Phase 4
Evaluation of Calcineurin-inhibitor Reduction With Conversion at 2 Months to Everolimus/Reduced Tacrolimus in Renal Transplant Recipients Following Campath® Induction
A Phase 4 study, sponsored by University of Toledo Health Science Campus.
- Completed
- Registry status
- Phase 4
- Development phase
- 55
- Enrollment target
NCT01935128 is a Phase 4 study that has completed, run by University of Toledo Health Science Campus. The registered enrollment target is 55 participants.
The verdict
NCT01935128, a Phase 4 study, has completed, sponsored by University of Toledo Health Science Campus.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 55 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate whether conversion to everolimus (Zortress®), allowing the elimination or reduction of calcineurin inhibitors, will reduce nephrotoxicity (measured by increased creatinine clearance) and lengthen overall graft (kidney transplant) survival (measured by 2-3 year graft survival).
Interventions
- DRUG Arm 1 Everolimus/Reduced dose tacrolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2013-07-03 |
| Est. Completion | 2020-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01935128
The ClinicalTrials.gov registry entry for NCT01935128 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Toledo Health Science Campus, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Arm 1 Everolimus/Reduced dose tacrolimus is the first listed.
NCT01935128 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01935128 about?
NCT01935128 is a clinical study titled "Evaluation of Calcineurin-inhibitor Reduction With Conversion at 2 Months to Everolimus/Reduced Tacrolimus in Renal Transplant Recipients Following Campath® Induction". The purpose of this study is to evaluate whether conversion to everolimus (Zortress®), allowing the elimination or reduction of calcineurin inhibitors, will reduce nephrotoxicity (measured by increased creatinine clearance) and lengthen overall graft (kidney transplant) survival (measured by 2-3 yea...
What is the current status of trial NCT01935128?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 55 participants. The study started on 2013-07-03. Estimated completion is 2020-07.
What interventions are being tested in trial NCT01935128?
The interventions under investigation include: Arm 1 Everolimus/Reduced dose tacrolimus (DRUG).
Who is sponsoring clinical trial NCT01935128?
This trial is sponsored by University of Toledo Health Science Campus, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.